Compare · ABT vs ANL
ABT vs ANL
Side-by-side comparison of Abbott Laboratories (ABT) and Adlai Nortye Ltd. (ANL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ANL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $155.32B, about 203.6x ANL ($762.8M).
- ANL has been more active in the news (7 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 6 for ANL).
- Company
- Abbott Laboratories
- Adlai Nortye Ltd.
- Price
- $89.10-2.33%
- $10.37-4.34%
- Market cap
- $155.32B
- $762.8M
- 1M return
- +7.93%
- -
- 1Y return
- -34.02%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest ANL
- Director Ji Ping acquired 136,667 units of American Depository shares (SEC Form 4)
- New insider Ye Xiaofeng claimed ownership of 159,455 units of American Depositary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Tse Alan Ming Lun
- Oppenheimer initiated coverage on Adlai Nortye Ltd. with a new price target
- CEO Lu Yang sold $132 worth of American Depositary Shares (10 units at $13.18), decreasing direct ownership by 0.01% to 99,990 units (SEC Form 4)
- New insider Lu Yang claimed ownership of 100,000 units of American Depositary Shares and claimed ownership of 16,990,000 units of Class B ordinary shares (SEC Form 3)
- New insider Tse Archie claimed ownership of 50,000 units of American Depository Share (SEC Form 3)
- SEC Form SCHEDULE 13G filed by Adlai Nortye Ltd.
- Amendment: SEC Form 3 filed by new insider Tang Kaiyang
- Amendment: SEC Form 3 filed by new insider Ji Ping